iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Pinnacle Private Wealth LLC

Pinnacle Private Wealth LLC cut its stake in iShares Biotechnology ETF (NASDAQ:IBBGet Rating) by 3.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,143 shares of the financial services provider’s stock after selling 576 shares during the period. iShares Biotechnology ETF accounts for about 0.8% of Pinnacle Private Wealth LLC’s portfolio, making the stock its 22nd largest position. Pinnacle Private Wealth LLC’s holdings in iShares Biotechnology ETF were worth $2,134,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Mascoma Wealth Management LLC raised its position in iShares Biotechnology ETF by 10.1% during the 1st quarter. Mascoma Wealth Management LLC now owns 1,127 shares of the financial services provider’s stock worth $147,000 after buying an additional 103 shares during the last quarter. Procyon Advisors LLC increased its holdings in shares of iShares Biotechnology ETF by 23.2% during the 1st quarter. Procyon Advisors LLC now owns 3,243 shares of the financial services provider’s stock valued at $423,000 after purchasing an additional 610 shares in the last quarter. HM Payson & Co. increased its holdings in shares of iShares Biotechnology ETF by 430.0% during the 4th quarter. HM Payson & Co. now owns 1,235 shares of the financial services provider’s stock valued at $188,000 after purchasing an additional 1,002 shares in the last quarter. G&S Capital LLC purchased a new position in shares of iShares Biotechnology ETF during the 1st quarter valued at approximately $3,980,000. Finally, Exane Derivatives increased its holdings in shares of iShares Biotechnology ETF by 55.6% during the 2nd quarter. Exane Derivatives now owns 1,271 shares of the financial services provider’s stock valued at $149,000 after purchasing an additional 454 shares in the last quarter. 60.42% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock traded down $1.35 during trading on Friday, reaching $115.38. The company had a trading volume of 197,289 shares, compared to its average volume of 1,872,065. iShares Biotechnology ETF has a 1-year low of $104.29 and a 1-year high of $174.45. The firm’s 50-day simple moving average is $125.20 and its 200 day simple moving average is $122.41.

About iShares Biotechnology ETF

(Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Recommended Stories

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.